University of Wisconsin - Carbone Cancer Center

University of Wisconsin Health

Madison, WI

Sorting 6 by

Accepting patients

BH-30236

A Phase 1/1b Open-Label, Dose Escalation, First-in- Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-leukemic Activity of the Orally Available CDC-Like Kinase (CLK) Inhibitor, BH-30236, in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML) or Higher-Risk Myelodysplastic Syndrome (HR-MDS)
  • CLK Inhibitor
  • Phase 1

Accepting patients

PedAL Screening

Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias
  • Phase 1/2

Accepting patients

MyeloMATCH Master Protocol

Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials
  • Genetic Sequencing
  • Phase 2

Accepting patients

Safety Study of Cord Blood Units

Safety Study of Unlicensed IND Cord Blood Units Manufactured by the National Cord Blood Program for Unrelated Transplantation
  • Allogeneic Stem Cell Transplant
  • Phase 2

Accepting patients

Cord Blood Units for Neutrophil Recovery

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
  • Cord Blood
  • Observational Trial

Accepting patients

TCRαβ+/CD19+ depleted Haploidentical HSCT

TCR-αβ+ and CD19+ Depleted KIR/KIR Ligand-mismatched Haploidentical Hematopoietic Stem Cell Transplant and Zoledronate for Pediatric Relapsed/Refractory Hematologic Malignancies and High Risk Solid Tumors
  • Allogeneic Stem Cell Transplant
  • Phase 1